Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24600949 | 0.90 | ADORA3 (0.61) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24600983 | 0.89 | ADORA3 (0.51) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24600978 | 0.89 | ADORA3 (0.59) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24600744 | 0.87 | ADORA3 (0.48) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24600732 | 0.87 | ADORA3 (0.48) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24600733 | 0.87 | ADORA3 (0.48) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24601487 | 0.87 | ADORA3 (0.47) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL24600752 | 0.87 | ADORA3 (0.57) | ADORA3ADORA1ADORA2BADORA2ATMIGD3 | |
| SCHEMBL24600854 | 0.86 | ADORA3 (0.61) | ADORA3ADORA1ADORA2BADORA2AADRA2A | |
| SCHEMBL24601081 | 0.85 | ADORA3 (0.69) | ADORA3ADORA1ADORA2BADORA2AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022143740-A1 | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江春禾医药科技有限公司 | 2022-07-07 | — | — | WO | disclosed |